| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Reviews |
Cold Spring Harbor Laboratory, Cold Spring Harbor, New York
Requests for reprints: Alea A. Mills, Cold Spring Harbor Laboratory, One Bungtown Road, Cold Spring Harbor, NY 11724. Phone: 516-367-6910; E-mail: mills{at}cshl.edu.
Key Words: 1p36 CHD5 chromosome engineering p53 Ink4/Arf
Genomic analyses of late-stage human cancers have uncovered deletions encompassing 1p36, thereby providing an extensive body of literature supporting the idea that a potent tumor suppressor resides in this interval. Although several genes have been proposed as 1p36 candidate tumor suppressors, convincing evidence that their encoded products protect from cancer has been scanty. A recent functional study identified chromodomain helicase DNA-binding protein 5 (CHD5) as a novel tumor suppressor mapping to 1p36. Here, we discuss evidence supporting the tumor-suppressive role of CHD5. Together, these findings suggest that strategies designed to enhance CHD5 activity could provide novel approaches for treating a broad range of human malignancies. [Cancer Res 2008;68(8):2551–6]
This article has been cited by other articles:
![]() |
M. Pigazzi, E. Manara, E. Baron, and G. Basso miR-34b Targets Cyclic AMP-Responsive Element Binding Protein in Acute Myeloid Leukemia Cancer Res., March 15, 2009; 69(6): 2471 - 2478. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. C. Prendergast Risk Factors for Cancer: From Cell to Microenvironment Cancer Reviews Online Content, May 1, 2008; 2008(5): 9 - 9. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |